Orally inhaled & nasal drugs
Executive Summary
FDA's Orally Inhaled & Nasal Drugs Subcommittee of the Pharmaceutical Science Advisory Committee will discuss dose response for locally-acting nasal sprays and aerosols July 17. The subcommittee's recommendations will be discussed at a July 19 meeting of the Pharmaceutical Science Advisory Committee